Faruqi & Faruqi Announces Securities Class Action Against Beta Bionics

Faruqi & Faruqi, LLP, a leading national securities law firm, has announced a potential securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX), a developer of automated insulin delivery systems for diabetes treatment. The firm is reminding investors who purchased or acquired securities in Beta Bionics between July 30, 2025, and February 24, 2026, of the November 3, 2026, deadline to seek the role of lead plaintiff in the lawsuit.

According to Faruqi & Faruqi, the lawsuit alleges that Beta Bionics and its executives violated federal securities laws by making false and misleading statements about the safety, efficacy, and commercial success of the company’s iLet insulin pump. The lawsuit claims that the company failed to disclose serious issues related to the device, including quality management system deficiencies, device malfunctions, and unreported serious injuries.

The complaint details that the FDA had issued a Form 483 following an inspection of Beta Bionics’ manufacturing facility. Despite this, the company repeatedly assured investors that the FDA's observations were only related to the criteria for deciding which customer complaints were reportable and that they did not reflect any underlying problems with the device. The firm further alleges that the FDA's findings actually reached the company’s quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself. The unreported events, the lawsuit claims, included serious injuries that required medical intervention.

Faruqi & Faruqi’s partner, James (Josh) Wilson, encourages investors who suffered losses to contact him directly to discuss their legal rights. Investors are advised to call the firm at 877-247-4292 or 212-983-9330 (Ext. 1310).

The lawsuit alleges that the company's misleading statements and failures to disclose critical information have caused significant financial losses for investors. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who will direct and oversee the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Faruqi & Faruqi, LLP, has a history of representing investors in securities litigation and has recovered hundreds of millions of dollars for shareholders. The firm encourages anyone with information regarding Beta Bionics' conduct to contact them, including whistleblowers, former employees, shareholders, and others.